Business
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeuti
About this update from Crispr Therapeutics Ag
[{"type":"image","alt":"CRISPR Therapeutics AG","displaySize":"","headline":null,"caption":"CRISPR Therapeutics AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":276,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/ed58450e4b2a421b0b66e4e87a2ce743"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pyAl4296SnwrvZ1qAcTTDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ed58450e4b2a421b0b66e4e87a2ce743","width":276,"height":300}},"lazy":false},{"type":"text","content":" -2026 is poised to be a data- and milestone-rich year across the portfolio-","length":75,"tagName":"p"},{"type":"text","content":"-CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-","length":83,"tagName":"p"},{"type":"text","content":"-Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases-","length":132,"tagName":"p"},{"type":"text","content":"-Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities-","length":136,"tagName":"p"},{"type":"text","content":"ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated 2026 milestones.","length":295,"tagName":"p"},{"type":"text","content":""Entering 2026, CRISPR Therapeutics is well positioned, with CASGEVY® gaining momentum, and multiple programs with encouraging data advancing rapidly through clinical trials across a diverse set of therapeutic areas,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Across the portfolio, clinical data demonstrated the transformative potential of CTX310™ for patients suffering from severe cardiovascular disease, as well as zugo-cel in oncology and autoimmune diseases. We also added a siRNA pillar through our partnership with Sirius and are advancing our lead siRNA asset, CTX611™ targeting Factor XI through the clinic. Beyond these clinical stage programs, we have multiple additional assets in preclinical development that leverage our best-in-class advanced editing pl...